Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial

BACKGROUND: Immunity to mosquito salivary proteins could provide protection against multiple mosquito-borne diseases and significantly impact public health. We evaluated the safety and immunogenicity of AGS-v PLUS, a mosquito salivary peptide vaccine, in healthy adults 18–50 years old. METHODS: We c...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman-Klabanoff, DeAnna J., Birkhold, Megan, Short, Mara T., Wilson, Timothy R., Meneses, Claudio R., Lacsina, Joshua R., Oliveira, Fabiano, Kamhawi, Shaden, Valenzuela, Jesus G., Hunsberger, Sally, Mateja, Allyson, Stoloff, Gregory, Pleguezuelos, Olga, Memoli, Matthew J., Laurens, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700263/
https://www.ncbi.nlm.nih.gov/pubmed/36436281
http://dx.doi.org/10.1016/j.ebiom.2022.104375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700263/
https://www.ncbi.nlm.nih.gov/pubmed/36436281
http://dx.doi.org/10.1016/j.ebiom.2022.104375

Ejemplares similares